Finch Therapeutics' market value is the price at which a share of Finch Therapeutics trades on a public exchange. It measures the collective expectations of Finch Therapeutics Group investors about its performance. Finch Therapeutics is trading at 14.29 as of the 24th of January 2026. This is a 0.63 percent increase since the beginning of the trading day. The stock's open price was 14.2. With this module, you can estimate the performance of a buy and hold strategy of Finch Therapeutics Group and determine expected loss or profit from investing in Finch Therapeutics over a given investment horizon. Check out Finch Therapeutics Correlation, Finch Therapeutics Volatility and Finch Therapeutics Alpha and Beta module to complement your research on Finch Therapeutics.
Please note, there is a significant difference between Finch Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Finch Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Finch Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Finch Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Finch Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Finch Therapeutics.
0.00
10/26/2025
No Change 0.00
0.0
In 2 months and 31 days
01/24/2026
0.00
If you would invest 0.00 in Finch Therapeutics on October 26, 2025 and sell it all today you would earn a total of 0.00 from holding Finch Therapeutics Group or generate 0.0% return on investment in Finch Therapeutics over 90 days. Finch Therapeutics is related to or competes with Celyad Oncology, Starpharma Holdings, Charlottes Web, Zenith Capital, and Positron Corp. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally admin... More
Finch Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Finch Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Finch Therapeutics Group upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Finch Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Finch Therapeutics' standard deviation. In reality, there are many statistical measures that can use Finch Therapeutics historical prices to predict the future Finch Therapeutics' volatility.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Finch Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Finch Therapeutics is not too volatile at the moment. Finch Therapeutics secures Sharpe Ratio (or Efficiency) of 0.059, which denotes the company had a 0.059 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Finch Therapeutics Group, which you can use to evaluate the volatility of the firm. Please confirm Finch Therapeutics' Mean Deviation of 1.49, coefficient of variation of 953.63, and Downside Deviation of 2.3 to check if the risk estimate we provide is consistent with the expected return of 0.11%. Finch Therapeutics has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.12, which means not very significant fluctuations relative to the market. As returns on the market increase, Finch Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Finch Therapeutics is expected to be smaller as well. Finch Therapeutics right now shows a risk of 1.87%. Please confirm Finch Therapeutics total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to decide if Finch Therapeutics will be following its price patterns.
Auto-correlation
-0.47
Modest reverse predictability
Finch Therapeutics Group has modest reverse predictability. Overlapping area represents the amount of predictability between Finch Therapeutics time series from 26th of October 2025 to 10th of December 2025 and 10th of December 2025 to 24th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Finch Therapeutics price movement. The serial correlation of -0.47 indicates that about 47.0% of current Finch Therapeutics price fluctuation can be explain by its past prices.
Other Information on Investing in Finch Pink Sheet
Finch Therapeutics financial ratios help investors to determine whether Finch Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Finch with respect to the benefits of owning Finch Therapeutics security.